Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 22,714,161 shares, a growth of 8.6% from the October 14th total of 20,910,269 shares. Based on an average daily volume of 1,239,566 shares, the short-interest ratio is currently 18.3 days. Currently, 22.1% of the company’s shares are sold short.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 6.28 on Friday. The company has a 50 day moving average price of $5.11 and a 200-day moving average price of $5.47. Keryx Biopharmaceuticals has a 52-week low of $2.80 and a 52-week high of $7.80. The firm’s market cap is $665.43 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.19. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. The business earned $6.30 million during the quarter, compared to the consensus estimate of $5.53 million. During the same period in the prior year, the firm earned ($0.29) EPS. The business’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, analysts expect that Keryx Biopharmaceuticals will post ($1.41) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of KERX. Price T Rowe Associates Inc. MD boosted its stake in shares of Keryx Biopharmaceuticals by 58.9% in the third quarter. Price T Rowe Associates Inc. MD now owns 56,946 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 21,100 shares during the period. Marco Investment Management LLC boosted its stake in shares of Keryx Biopharmaceuticals by 6.5% in the third quarter. Marco Investment Management LLC now owns 49,350 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 3,000 shares during the period. Knoll Capital Management LP purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter worth approximately $1,030,000. Endurant Capital Management LP purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter worth approximately $616,000. Finally, Green Square Capital LLC purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter worth approximately $135,000. 62.28% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on the company. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Vetr downgraded Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.11 price objective on the stock. in a research note on Thursday, November 10th. FBR & Co set a $7.00 price objective on Keryx Biopharmaceuticals and gave the stock a “hold” rating in a research note on Friday, November 11th. Brean Capital downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Finally, Maxim Group raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $8.28.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

5 Day Chart for NASDAQ:KERX

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.